SCHEMBL25398951

SCHEMBL25398951

Cc1cc(SCc2nnc(-c3ccc(F)c(Cl)c3)s2)ccc1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCTL Q9NXS2 2/20 0.41
QPCT Q16769 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PPARD Q03181 8/20 0.37
PIK3CA P42336 1/20 0.36
PPARA Q07869 5/20 0.36
PPARG P37231 2/20 0.36
MAPT P10636 2/20 0.36
SNCA P37840 1/20 0.35
PTPRE P23469 1/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
FYN P06241 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30579872 1.00 QPCTL (0.41) QPCTLQPCTSMN1; SMN2POLBNPSR1
SCHEMBL31408959 0.90 QPCTL (0.43) QPCTLQPCTSMN1; SMN2POLBNPSR1
SCHEMBL25399067 0.90 QPCTL (0.43) QPCTLQPCTSMN1; SMN2POLBNPSR1
SCHEMBL25397915 0.84 QPCTL (0.39) QPCTLQPCTSMN1; SMN2POLBNPSR1
SCHEMBL31333764 0.83 PPARD (0.54) QPCTLQPCTPPARDPPARAPPARG
SCHEMBL25398403 0.83 QPCTL (0.43) QPCTLQPCTSMN1; SMN2POLBPPARD
SCHEMBL31408949 0.83 PPARD (0.56) PPARDPPARAPPARGMAPTHPGD
SCHEMBL25396899 0.83 PPARD (0.56) PPARDPPARAPPARGMAPTHPGD
SCHEMBL25397535 0.81 PPARD (0.60) PPARDPPARAPPARG
SCHEMBL25398468 0.81 TSHR (0.45) QPCTLQPCTPPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197363-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME CUREVERSE INCORPORATED (KR) 2025-06-19 US disclosed
EP-4495106-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2025-01-22 EP disclosed
WO-2023177146-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME 재단법인 대구경북첨단의료산업진흥재단 2023-09-21 WO disclosed
WO-2023177146-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME 재단법인 대구경북첨단의료산업진흥재단 2023-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197363-A1 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME PPARD, PPARG, PPARA QPCTL 2697/4885QPCT 2400/4885SMN1; SMN2 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.